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Abstract
Background: Deep Bleeder Acoustic Coagulation (DBAC) is an ultrasound image-guided high-intensity focused
ultrasound (HIFU) method proposed to automatically detect and localize (D&L) and treat deep, bleeding, combat
wounds in the limbs of soldiers. A prototype DBAC system consisting of an applicator and control unit was developed
for testing on animals. To enhance control, and thus safety, of the ultimate human DBAC autonomous product system,
a thermal coagulation strategy that minimized cavitation, boiling, and non-linear behaviors was used.
Material and methods: The in vivo DBAC applicator design had four therapy tiles (Tx) and two 3D (volume)
imaging probes (Ix) and was configured to be compatible with a porcine limb bleeder model developed in this
research. The DBAC applicator was evaluated under quantitative test conditions (e.g., bleeder depths, flow rates,
treatment time limits, and dose exposure time limits) in an in vivo study (final exam) comprising 12 bleeder
treatments in three swine. To quantify blood flow rates, the “bleeder” targets were intact arterial branches, i.e.,
the superficial femoral artery (SFA) and a deep femoral artery (DFA). D&L identified, characterized, and targeted
bleeders. The therapy sequence selected Tx arrays and determined the acoustic power and Tx beam steering,
focus, and scan patterns. The user interface commands consisted of two buttons: “Start D&L” and “Start Therapy.”
Targeting accuracy was assessed by necropsy and histologic exams and efficacy (vessel coagulative occlusion) by
angiography and histology.
Results: The D&L process (Part I article, J Ther Ultrasound, 2015 (this issue)) executed fully in all cases in under
5 min and targeting evaluation showed 11 of 12 thermal lesions centered on the correct vessel subsection, with
minimal damage to adjacent structures. The automated therapy sequence also executed properly, with select
manual steps. Because the dose exposure time limit (tdose ≤ 30 s) was associated with nonefficacious treatment,
60-s dosing and dual-dosing was also pursued. Thrombogenic evidence (blood clotting) and collagen
denaturation (vessel shrinkage) were found in necropsy and histologically in all targeted SFAs. Acute SFA
reductions in blood flow (20–30 %) were achieved in one subject, and one partial and one complete vessel
occlusion were confirmed angiographically. The complete occlusion case was achieved with a dual dose (90 s
total exposure) with focal intensity ≈500 W/cm2 (spatial average, temporal average).
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Conclusions: While not meeting all in vivo objectives, the overall performance of the DBAC applicator was
positive. In particular, D&L automation workflow was verified during each of the tests, with processing times well
under specified (10 min) limits, and all bleeder branches were detected and localized. Further, gross necropsy and
tissue examination confirmed that the HIFU thermal lesions were coincident with the target vessel locations in over
90 % of the multi-array dosing treatments. The SFA/DFA bleeder models selected, and the protocols used, were the most
suitable practical model options for the given DBAC anatomical and bleeder requirements. The animal models were
imperfect in some challenging aspects, including requiring tissue-mimicking material (TMM) standoffs to achieve deep
target depths, thereby introducing device-tissue motion, with resultant imaging artifacts. The model “bleeders” involved
intact vessels, which are subject to less efficient heating and coagulation cascade behaviors than true puncture injuries.
Background
Deep Bleeder Acoustic Coagulation (DBAC)
A Deep Bleeder Acoustic Coagulation (DBAC) cuff sys-
tem is an ultrasound device intended to cauterize deep,
bleeding, combat limb wounds of soldiers while in the
field. This paper is a companion to the Part I article [1]
that describes the development and in vitro (phantom)
testing of a DBAC cuff research prototype. The DBAC
system is designed to operate autonomously, first to detect
and localize (D&L) deep arterial bleeders with ultrasound
imaging and treat them using high-intensity focused ultra-
sound (HIFU) [1]. The primary objective of the project
described herein was the demonstration of acoustic co-
agulation using an automated DBAC device in an animal
model over a range of target depths, bleeder flow rates,
and treatment time limits as defined in the project con-
tract.1 The device tests were administered in an in vivo
test bed final exam series of evaluations developed and
performed in collaboration with two laboratories. A
high-level outline of the required test and parameter-
range conditions is shown in Table 1.
DBAC animal model
In vivo test conditions differed from those for the in vitro
case [1], in part because bleeder flow rates and depths
in an animal cannot be as precisely prescribed as in a
phantom due to physiologic variability and the effects
of invasive instrumentation. For in vivo DBAC testing
to occur, animal model development was therefore re-
quired, with a variety of candidate animal models being
evaluated, both analytically and through in vivo experi-
ments. The animal selected was to preferably have human
adult limb-like “cuff compatible” anatomy, and the model
was to enable quantitative control of bleeder blood flow
and vascular parameters. These included maintaining
suitable normal and bleeder arterial flow waveforms
and providing an in vivo “tourniquet function,” whereby
the bleeding could be stopped during the HIFU treat-
ment, as explained in reference [1].
Model development involved evaluating ovine, canine,
and porcine species, focusing on experimentally evaluat-
ing both cervical (carotid artery) bleeders and femoral
artery bleeders. Integral to the final model selection was
the conclusion that a full (360°) cuff DBAC device, such
as developed and described in [1], could not be tested in
a practical animal model and hence required some
compromise.
The compromise was to test a DBAC cuff “subsection”
on the hind limbs of large swine, using the intact (not
punctured) superficial femoral artery (SFA) as the simu-
lated bleeder and “bleeder track” (Fig. 1). While an actual
arterial puncture may have more closely represented
Table 1 Outline of test conditions/objectives for in vivo DBAC testing
Milestone Most challenging
problem
Milestone specification Treatment speed Device operation
DBAC hemostasis test
condition/objective
Slow bleeder injury Slow bleed in
small vessel
5 ml/min Achieve hemostasis








Fast bleeder injury Fast bleed in
large vessel
100 ml/min







Thermal lesioning limited to




Skin burn MTSD≤ 52 °C
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arterial bleeding, this approach would not have allowed
for practical monitoring and control of bleeding flow
rates, and it would not easily enable the needed “tourni-
quet function.” A continuation segment of the femoral
artery beyond the SFA bifurcation, referred to here as
the deep femoral artery (DFA), was also used as a bleeder
in some animals to access the deepest bleeder targets.
Material and methods
In vivo animal DBAC device
Several design iterations of the in vivo DBAC prototype
device were required to adequately modify the in vitro
cuff geometry into a subsection of the prototype “human
cuff” suitable for the intended testing. The design, opti-
mized using computational modeling and the animal
model development tests, comprised an elliptically shaped
rigid plastic support structure incorporating a sealed,
water-filled bolus for acoustic coupling, with the positions
of the 2D therapy arrays (the HIFU “tiles” or “Tx”) and
volume imaging arrays (“Ix”) being identical to a contigu-
ous section of the full cuff prototype described in [1]. The
power and control unit was architecturally (acoustically,
electronically, and in software) very similar to that used in
the in vitro DBAC research prototype. Figure 2a shows
the in vivo applicator configuration superposed on the
porcine groin. To achieve the required bleeder depth
ranges (3.5 to 12.5 cm) using the shallow SFA (≈2-cm
deep), an added “tissue layer” was placed between the skin
surface of the animal and the DBAC applicator. Figure 2b
depicts this arrangement in which acoustically and ther-
mally appropriate tissue-mimicking material (TMM)
standoff layers of different thicknesses (depending on
desired bleeder depth) were placed on the porcine
groin. To provide a flexible and conformal standoff, a
10 % polyvinyl alcohol (PVA)-based TMM with aluminum
oxide attenuating scatterers was used [2]. Up to two
TMM layers of different thicknesses were used to achieve
the deepest required bleeder target depths.
The applicator’s cuff-like curvature was implemented
by having two surfaces set at a 30° angle between them,
whereby each surface substituted for a cuff “panel” of
the research prototype, each having two Tx’s and one
Ix. Imaging was accomplished with Siemens 4Z1c
probes (acoustic center frequency, fc = 2.5 MHz) con-
nected to a Siemens ACUSON SC2000™ ultrasound
imaging system [1]. The in vivo applicator enabled test-
ing of key DBAC cuff functionality on the porcine SFA
model, which had arteries of an appropriate physical
scale and allowed vascular access for blood flow quanti-
tative control, including a tourniquet mechanism.
To estimate individual Tx powers and beam patterns
during dosing, and to provide device positioning guid-
ance, the treatment tissue thermal responses were com-
putationally simulated in finite element method (FEM)
models (ANSYS v.12 and ANSYS Multi-Physics codes;
ANSYS Inc., Canonsburg, PA, USA). The model was based
on the anatomy and coordinates of the SFA bleeders and
the geometry of the Tx tiles, extracted from applicator-
on-animal computer-assisted design (CAD) models (Solid-
Works, Dassault Systemes Solidworks Corp., Waltham,
MA, USA), as in Fig. 2. The acoustic fields were input as
distributed energy sources into the FEM tissue models,
which incorporated the bio-heat transfer equation [3] to
take into account perfusion influences on temperatures.
Sample end-of-dose temperature (Teod) distributions are
shown in Fig. 3, with detailed focal heating volumes in Fig. 4
Fig. 1 DBAC in vivo bleeder model: porcine superficial femoral artery (SFA). CAD drawing from CT scans and angiograms of vascular anatomy.
The sheath was inserted into the SFA, and depending on the test subject, the bleeder was defined to be 10 mm or 20–25 mm distal to the SFA
bifurcation with the common femoral artery (CFA)
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(generated according to the geometry of Fig. 2). Simulations
of the thermal response of the target vessel (e.g., SFA blood
flow convective effects) are discussed below.
In the Fig. 4 example, the time-averaged acoustic power
for each Tx was ≈50 W with a dosing time of 60 s. The
70 °C iso-surface-enclosed volume in Fig. 4a approximates
the smallest typical lesion. Since tiles on the in vivo appli-
cator did not have as wide an angular distribution of
acoustic power as a cuff, the resulting heated region shape
(see Fig. 4b), while having a circular lateral cross-section,
is long in the axial direction.
In vivo test bed protocol
The animal model and test protocols were developed
using a total of 45 swine, with the in vivo final exam
and its finalization utilizing an additional five animals.2
Immediately prior to the final exam, practice tests on
two swine were used to finalize the protocol and verify
the compatibility and suitability of the test measurement
methods. In the final exam, performed in accordance with
approved Texas A&M Institute for Preclinical Studies
(TIPS) Animal Use Protocols [4], 12 bleeder treatments
were performed in three animals.
Animals were anesthetized, and the caudal ventral ab-
domen and inner thighs were prepared using a cream
depilatory to remove all hair. Systemic heparinization
was used due to the invasive instrumentation, and base-
line ultrasound gray scale imaging (B-mode), color-flow
Doppler, and spectral Doppler (SD) ultrasound scans
were performed to characterize the vascular anatomy.
Baseline fluoroscopy (Fig. 5) was also performed, with
both right and left common carotid arteries being surgi-
cally exposed and 8- to 10-French catheter introducers
positioned in each. A multi-side-hole diagnostic catheter
(for dye injection) was advanced under fluoroscopic guid-
ance to the distal aorta, and angiography of the hind
limb vasculature was performed pre-treatment.
For blood flow control during treatment, balloon-tipped
catheters (with balloons 16- to 18-mm diameter; 4-cm







Fig. 2 Experimental configuration during DBAC animal testing. Shown are CAD model depictions of the following: a the in vivo DBAC applicator
with the 3D imaging probes (4Z1c) on porcine groin targeting SFA bleeder; b in vivo DBAC device used with TMM tissue standoffs targeting
bleeders and different depths
a b
Fig. 3 Example of simulated cross-sectional temperature distributions. To guide applicator positioning and TMM standoff requirements, a 3D
acousto-thermal FEM models were used incorporating a perfused anterior limb muscle field near the SFA. b Inset showing a Teod distribution
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diagnostic catheter to an aortic position distal to the
renal arteries but proximal to the external iliac arteries.
The balloon catheter was inflated and, using the previ-
ously positioned diagnostic catheter, an aortogram was
performed to confirm appropriate positioning of the
balloon catheter, as well as to enable complete occlu-
sion of the distal aorta. This catheter access, along with
stopcock manipulation in the SFA-resident catheter,
was used to alter flow in the common femoral and SFA
arteries. This allowed fine adjustment of volumetric
bleed rates and complete occlusion of femoral arterial
flow (the “tourniquet” function) during therapy. B-mode
and Doppler flow scans (Fig. 6) were repeated with the
balloon catheter first deflated, then gradually inflated to
confirm that flow could be decreased, and ultimately
stopped, based on the degree of balloon inflation. This
process was also repeated immediately prior to euthan-
asia to confirm the reliability of the “tourniquet” func-
tion of the aortic balloon.
For animal stability, the “tourniquet shut-off” could
not be maintained throughout the therapy periods in
some “extended dose” treatments, since the fully in-
flated balloon catheter cut off perfusion to almost half
of the animal. To expose the distal SFA for placement
of the introducer/sheath, a small surgical cut-down was
performed and a 4-French introducer/sheath advanced
approximately 2–4 cm into the bleeder arterial lumen
(Fig. 1).
 Treatment volume (70°C iso-surface)  Treatment volume (52°C iso-surface)a b
Fig. 4 Sample simulated thermal treatment volumes produced by four Tx tiles of the in vivo DBAC applicator. Enclosed end-of-dose tissue
volumes are at and above the iso-surface temperature indicated. a indicates the end-of-dose inner core (target tissue) volume over a therapeutic
temperature threshold of 70 °C; b shows the larger region surrounding the core target region that exceed 52 °C (all dimensions are in mm)
Fig. 5 Pre-treatment angiograms of both the right and left rear limbs. In all tests, these steps were taken to characterize the vascular anatomy
prior to instrumentation and to provide baseline images to which the post-therapy angiograms could be compared
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Using this setup, a series of in vivo controlled bleed
studies were performed using the balloon catheter degree-
of-inflation and introducer catheter stopcock settings. The
applicator was also evaluated for compatibility with the
animal preparation. “Bleeder” flow waveforms were cre-
ated by altering inflow into the common femoral artery
(CFA) using the balloon-tipped catheters and allowing the
catheter introduced into the SFA to vent its flow to the
atmosphere. During “bleeder tract” characterization by the
DBAC system, a bleeder waveform was defined by a low
Resistive Index (RI<0.75) [1]. Volumetric flow rates were
confirmed by collecting shed blood over a measured
time period into a clean bowl and then transferring that
blood into a validated graduated cylinder. Importantly,
once shed blood volume was measured, it was returned
to the study subject to preserve the hemodynamic sta-
bility of the model. This process was repeated during
the testing sessions to ensure accurate volumetric bleed
data.
It was found in some animals after the SFA cathe-
terization had been completed that the bleeder target
did not meet the deepest requirements, even with the
thickest (6 cm) standoff. It was in these situations that
the deep femoral artery (DFA) was selected as the
bleeder target. Regrettably, the DFAs under these cir-
cumstances could not be instrumented with introducer
catheters (Fig. 1).
Regarding test conditions, the control of depth and
blood flow rate were categorized into coarse ranges, as
follows:
Bleeder rate and depth range test condition objectives:
The efficacy objective was to produce full obstruction
of the lumen of the SFA via thermal coagulation mecha-
nisms induced by confocal beams from the in vivo
DBAC applicator. The SFA bleeder model had the ad-
vantage of the blood not being prone to spontaneous
coagulation (no device/blood contact in the region), and
the bleeder target region of interest was free of stitches,
vascular clamps, or other hardware.
Following completion of an in vivo study, angiograms
were repeated, and the adequacy of anticoagulation was
again confirmed before the study subjects were eutha-
nized. Complete postmortem examinations of the vascular
regions of interest were performed, including lesions being
photographically documented and samples being obtained
for histologic evaluation.
The TMM standoffs were ultimately determined to
have a non-negligible impact on acoustic performance
(for both imaging and therapy). For this reason, it was
useful to deploy a backup imaging probe (in addition to
the 4Z1c) to corroborate and supplement the 4Z1c, par-
ticularly for the deepest bleeders. Accordingly, although
not part of the DBAC applicator design, a 2D imaging
probe with more penetration (Siemens C7F2) was in-
stalled on the applicator (Fig. 7a). The applicator had a
closed water-filled coupling compartment surrounding
the transducers, created via a 50-μm polyurethane mem-
brane stretched across the bottom opening of the appli-
cator and secured with two O rings (Fig. 7a, b). Fill and
vent ports were used for priming the coupling compart-
ment with degassed water, which also enabled air to be
purged. As appropriate, the applicator was either posi-
tioned on the subject’s skin surface or the TMM standoff,
Fig. 6 Spectral Doppler (SD) flow confirmation of “tourniquet” function of the intra-aortic balloon. Flow in the femoral artery was eliminated by
balloon inflation and returned rapidly with balloon deflation. SD evaluation was repeated following therapy
Slow bleed Blood flow rate = 5 to 60 ml/min
Fast bleed Blood flow rate = 60 to 100+ml/min
Shallow depth Bleeder depth = 3.75 to 8 cm
Deep depth Bleeder depth = 8 to 12.5 cm
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with acoustic gel or lotion used to couple the interfaces
(i.e., membrane TMM and TMM animal skin). The in vivo
applicator and the TMM standoff layers were held in place
on the animal with clamps (Fig. 7a, b). TMM-associated
imaging noise occurred primarily at the TMM-TMM and
TMM-skin interfaces, and this noise was addressed in part
by the use of custom image processing algorithms designed
to filter and suppress noise at the interfaces.
Treatment workflow and automation
Similar to the in vitro DBAC treatment [1], an objective
was a “two-button” treatment procedure available to the
operator: Start D&L and Start Therapy. As depicted in
Fig. 8, D&L included (a) B-mode and power Doppler
mode acquisitions, (b) bleeder detection, (c) bleeder (or
normal branch) characterization via resistive index, and
therapy marker placement on the vessel target. Figure 9
shows a sample power Doppler image used for vascular
branch characterization and bleeder (SFA branch)
localization. If a DFA vessel segment was the designated
target, the therapy marker was placed manually (since
the DFA was not catheterized). The communication be-
tween D&L and therapy subsystems was also established at
the end of the D&L sequence.
Upon D&L sequence completion, an automatic pause
state was entered, to allow synchronization with the ani-
mal preparation workflow involving the arterial catheter
balloon inflation. After inflation of the balloon catheter,
simulating tourniquet deployment, the “Start Therapy” but-
ton was launched, which completed the treatment cycle. Tx
array driver voltages, whose values were determined auto-
matically, were manually set on the DBAC power supply.
After the target location was passed from D&L processing
to the therapy subsystem automatically, the dose was
Fig. 7 In vivo DBAC device and final exam treatment setup. a Applicator showing four therapeutic array tiles, the two 4Z1c 3D imaging probes,
and backup 2D C7F2 imaging probe; b applicator being positioned for treatment on PVA TMM standoff (secured by Manfrotto™ clamps attached
to surgical table)
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calculated, the recruited therapy tiles were selected, and the
duty cycles for each individual Tx were determined, all
automatically. The targeting and therapy mode states on
the ACUSON SC2000 system were also automatically set.
Of the 12 bleeder treatments, the DFA was used in 6
and could not exhibit “bleeder” pulsatility waveforms since
no venting (via catheterization) was available. For the
“DFA bleeder,” a manual (non-automated) therapy marker
was thus used to target the bleeder. While the SFA work-
flow was fully automated, the DFA had this manual step
(Fig. 8).
Targeting and dosing
DBAC closed-loop targeting, based on thermal strain
imaging of the focus, and closed-loop dosing, based
on recurrent neural network (RNN) acoustic therm-
ometry, were demonstrated earlier to be reasonably
effective for the in vitro cuff prototype testing in
phantoms [1]. However, only a few animal experiments
incorporating targeting and thermometry data acquisition
were performed prior to the final exam. Thus, available
data was insufficient for “training” and validating the in
vivo acoustic radiation force impulse (ARFI) imaging and
RNN thermometry algorithms, particularly with in vivo
tissue motion. Therefore, while automated closed-loop
targeting and dosing was not used formally to guide treat-
ments, RNN thermometry (based on ex vivo liver data) was
used to visually assess the locations of energy delivery
relative to the desired targets and to estimate dosing rela-
tive temperatures. The in vivo automated targeting was in-
stead achieved by D&L alone, without iterative targeting
correction as described in [1]. In this processing, the
bleeder location was converted to coordinates in “therapy
space,” and dosing power levels and beam patterns were
then auto-computed to produce coagulative necrosis
at that location under fixed dose exposure time conditions.
The objective that Teod at the skin surface not exceed
52 °C under worst case dosing conditions was tested as
follows: (a) a deep target was selected in a single animal
(away from the SFA and DFAs being treated); (b) a
75-μm butt-welded thermocouple was placed at the
interface between the PVA (virtual “skin”) and the in
vivo applicator fluid compartment skin-contacting
membrane; (c) using the geometry of the tiles and the
target for guidance, the thermocouple junction was
positioned within the cross-section of the least steered
therapy beam at the interface; and (d) a maximum power
dose at 60-s exposure was delivered and the resulting
thermocouple temperature rise recorded.
Results
Detection and localization (D&L)
D&L assessment focused on the following main mea-
sures: automated D&L workflow success, detection of
both slow and fast bleed injuries, achieving and detect-
ing the deepest bleeds, and keeping combined D&L plus
therapy time ≤30 min.
Fig. 8 Detection and localization (D&L) workflows
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Figure 10 and Table 2 summarizes the D&L test condi-
tions and bleeder characterization success rates. Overall,
D&L results were positive with all bleeder branches be-
ing detected and localized and with one-button D&L
automation workflow verified during each of the tests.
Image acquisition plus D&L processing times were less
than 5 min for the first bleeder, well under the limit of
10 min. The 4Z1c-probe-based D&L times for the SFA
averaged 265 s for first bleeders, and 25 s for subsequent
bleeders. The C7F2 probe was used for DFA-vessel D&L
(again, manually assigning location markers) and had an
average D&L time of 203 s. Two specific bleeder charac-
terizations were problematic in being incorrectly charac-
terized as non-bleeders; both were slow bleeders (24 and
5 ml/min cases).
Targeting and dosing
Figure 11 displays a time series of RNN temperature
maps from a single animal treatment to illustrate the use
of RNN thermometry to ascertain whether acoustic
energy was delivered to desired target locations. The
SFA and DFA coagulation results are shown in Table 3.
The accuracy of targeting (“Lesion” column in Table 3)
was by gross necropsy evaluation, with histopathology of
border samples from the lesions produced. Immediate
postmortem tissue examinations were performed to as-
sess the location (in comparison with intended target
locations) and extent of the thermal lesioning in the
vessel target areas. These visual inspections confirmed
that the lesions were almost exclusively coincident with
the distal branch locations targeted (Fig. 12). Gross nec-
ropsy confirmed the presence of lesions in appropriate
anatomic locations in 11 of the 12 (91.6 %) targets, as in-
dicated in Table 3. Measurement or calculation of entire
lesion volumes could not be performed accurately while
still allowing dissection and documentation of lesions.
Lesion diameter was measured, however, and ranged be-
tween 7 and 19 mm, with most approximately 11 mm.
Coagulation endpoints
Although the maximal focal intensities for individual
(static) HIFU beams were ≈1600 W/cm2, the intensities
reported in Table 3 reflect values that were spatially
averaged over the scanned multi-foci pattern (an 8-mm
diameter “dithering” pattern, as discussed in [1]) then
derated for attenuation along the beam path for all Tx
beams. The intensities are the result of superposition of
all the Tx beam foci.
The results of the two practice-animal tests revealed a
pattern of not achieving definitive efficacy (hemostasis;
defined as arterial occlusion) using the required ≤30-s
dose regimes. Accordingly, dose escalation, including
applying two doses, was used in subsequent animals,
achieved primarily by extending the total cumulative
high power exposure times beyond 30 s (Table 3). Of
significance in the cases of dual dosing, tissue cooldown
to baseline occurred between doses due to the extended
times (5 to 37 min) needed to measure blood flow rates
after the first dose (involving balloon catheter deflation,
hemodynamic stabilization, and re-inflation). Regarding
efficacy, acute reductions in blood flow (20 and 30 %;
measured 10 min post-dose) were found for two SFA
targets in animal #101. One partial vessel occlusion
(Fig. 13b) and one complete occlusion (Fig. 13a) were
confirmed angiographically.
Histopathology also showed increased blood clotting
(thrombogenesis) for the latter tests as acoustic dose
exposures were increased. Figure 14 shows the histologic
changes in the target vessel of animal #103 (Figs. 12
and 13a), in which the right femoral artery became
completely occluded (post-dosing) by thermally in-
duced thrombus. Particles of thrombus material were
noted and removed from the lumen during examination.
The degree of change in the SFA branch in this treatment
Fig. 9 Image of limb vascularity in a test subject with SFA bleeder
branch. Compound 3D power Doppler image with D&L automated
algorithm-placed markers (crosses) denoting normal branches
(bifurcations), vascular centerline markers, and the bleeder target (green
cross), here 10 mm distal to the bleeder SFA branching point
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Fig. 10 D&L bleeder test cases in the in vivo test bed. General test range area avoided is depicted with the red-box outline. Legend: blue diamond
symbol = practice animal 1; blue square symbol = practice animal 2; red diamond symbol = test animal 1; red square symbol = test animal 2; triangle
red symbol = test animal 3
Table 2 Summary of in vivo final exam D&L results
Exp. no. Side Bleed type Bleed depth (mm) Depth category Flow rate (ml/min) Flow rate category Bleed character correct?
1 L SFA 49 Shallow 104 Fast Y
2 L DFA 115 Deep N/A
3 R SFA 52 Shallow 95 Fast Y
4 R DFA 78 Deep N/A
5 R SFA 52 Shallow 24 Slow Y
6 R SFA 52 Shallow 24 Slow Na
7 R DFA 105 Deep N/A
8 L SFA 92 Deep 12.5 Slow Y
9 L SFA 92 Deep 83 Fast Y
10 L DFA 110 Deep N/A
11 R DFA 110 Deep N/A
12 R SFA 56 Shallow 5.2 Slow Y
13 R SFA 56 Shallow 5.2 Slow Na
14 L DFA 108 Deep N/A
15 L SFA 52 Shallow 88 Fast Y
Exps 1–4: animal #101; Exps 5–10: animal #104; Exps 11–15: animal #103
aBleeder incorrectly characterized by algorithm as non-bleeder
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was quite evident during gross postmortem examination
as well. Despite complete occlusion of the SFA in this
case, the cross-section of the parent vessel (the CFA at
the branching point) was histologically normal, sup-
porting localization and targeting accuracy.
Targeting and therapeutic dosing for almost all cases
were sufficiently well controlled to yield minimal collat-
eral damage. Lesions created on the SFA, the primary
bleed target site, were consistently confined to the target
area with minimal or no changes noted in the parent
vessel (Fig. 15). The notable exception was animal #104
(test #5), showing partial occlusion, in which the parent
vessel showed evidence of modest histologic changes, as
well, and mild angiographic changes. In this case, the
target vessel had the most dramatic histologic changes
of the bleeder vessels treated in the series. Microscopic
evaluation of this treated SFA area showed loss of
endothelial lining, and approximately 80 to 90 % of the
cross-sections had acute necrosis (characterized by pyk-
notic loss of nuclei) and hyper-eosinophilia (with effaced
architecture) of smooth muscle cell cytoplasm. Addition-
ally, the lumen of the vasa vasorum, located in the adven-
titia, was distended by the blood coagulum.
The objective of maximum skin temperature, Teod ≤
52 °C, under worst case dosing conditions was met. A
target was selected at 10.8 cm depth (beneath the 6 cm
PVA standoff ), and a 60 s dose at maximum power,
211 Wac, was delivered. As measured by the thermo-
couple, the resulting surrogate skin (TMM surface)
ΔTeod ≈ 2.6 °C, equivalent to a maximum Teod = 39.6 °C.
Discussion
Detection and localization
All in vivo D&L depth and flow test conditions were
tested (noting that the deepest bleeder was 11.5 cm
depth; see below), and cumulative acquisition and D&L
time were kept under 5 min, well below the required
10-min limit. The lack of closed-loop targeting (depending
only on initially determined D&L coordinates) was not
significantly limiting since, in almost all cases, post-
treatment necropsy showed thermal lesioning approxi-
mately coincident with the SFA or DFA branches at
the target locations. Overall, D&L results were positive
(92 % success rate based on postmortem tissue exams). It
is understood that the importance of feedback-controlled
targeting would be greater in the case of a true DBAC
cuff, given that multiple beams must be confocal from a
surrounding 360° acoustic aperture.
Animal model
In investigating alternatives to obtain a physically deeper
target than the SFA, a complementary bleeder model prep-
aration involving the profunda femoral artery branch was
experimentally evaluated. Although potentially providing
deeper bleeder targets than the SFA, the profunda was
found difficult to instrument and perform the post-therapy
cut-down necropsy. Thus, the DFA was determined the
best alternate to the SFA.
The TMM standoffs enabled treatment of deeper bleeder
targets but requiring certain tradeoffs in test logistics and
acoustic performance. Although using multiple standoffs
to achieve the maximum depth of 12.5 cm was attempted,
the physical stability and imaging noise associated with this
setup rendered the 12.5-cm depth impractical. With the
thickest 6-cm standoff, the DFA often reached a depth of
12.5 cm but did so 40 mm from the bifurcation, a point
more caudal and lateral to the femur, where the target
would be so close to the bone that shadows/reflections
would have blocked/reflected the therapy beam (again, this
animal DBAC device had limited beam access compared to
Fig. 11 Target temperature evolution during dosing in in vivo
porcine muscle. Target is DFA, left hind limb. Left column: axial-
lateral plane views. Right column: axial-elevational views. Color bar:
ΔT = 0 °C to 20 °C (note: RNN thermometry was based on algorithm
training from ex vivo liver data). In the first three figures the beam
direction and focus are marked with white and black arrows,
respectively and the cross-section of the vessel is annotated with a
white circle
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a multi-tile cuff wrapping around a limb). As a comprom-
ise, a target along the DFA approximately 20–25 mm from
the bifurcation was chosen, making the deepest target
depth 11.5 cm (with standoff layers included).
As noted earlier, two D&L cases did not meet bleeder
characterization objectives (Table 2), both being slow
bleeders (5 and 24 ml/min). Attempts to go to the ex-
treme lower limit of the bleeder flow rate were influ-
enced by the individual test subjects (e.g., alterations in
both intra-aortic balloon inflation and stopcock manipula-
tion), producing variability in the flow rate. In addition to
potential variability of the low bleeder flow, it should be
noted that the 4Z1c is a cardiac probe and thus likely had
inadequate sensitivity in color-flow mode for this flow
regime and would have benefited from additional power
Doppler flow imaging mode (P-mode) optimization for
the low-flow application. Also contributing to decreased
flow sensitivity were the coupling and imaging noise chal-
lenges due to the TMM standoffs. Although the slow
bleeder D&L is truly challenging, it is speculated that
more in vivo practice experiments would have contributed
to optimizations improving this performance.
While developing the blood flow control approaches,
both the degree of intra-aortic balloon inflation and
stopcock manipulation were evaluated in detail. Using
the stopcock to regulate flow was found to have a dem-
onstrable impact on the waveform signature of the flow,
since blood pressure against the partial opening of the
stopcock could generate non-bleed signatures. In
contrast, using the balloon catheter to control the
flow in the descending aorta produced a slow flow
going through the superficial femoral artery with a
valid “bleed” spectral Doppler signature, but it also
quantitatively reduced the flow in the common fem-
oral artery. It was realized that neither of the two
techniques, individually, could provide both a realistic
flow in the SFA and produce a valid spectral Doppler
bleeding signature. As a consequence, the animal
model was slightly modified such that the stopcock
technique was used to generate a realistic flow rate in
the proximal and distal femoral artery, as well as the
SFAs, while the balloon catheter partial inflation tech-
nique was used to provide the bleed signatures during
D&L spectral Doppler acquisition.
Automated performance and device workflow
Although the DBAC automation objective was largely met
with a “two-button” treatment being satisfied, one manual
step (occurring between D&L and therapy) was required.
This derived from the fact that two separate imaging sys-
tems had to be used—one for the D&L workflow and the
other for the steps following initial D&L, including ther-
apy. This was because full integration of the system soft-
ware had not been completed by the date of the animal
study evaluation. It was thus required that, after D&L, im-
aging probes from the first imager had to be manually
switched to the other imager.
Table 3 Summary of in vivo test bed final exam therapy results
Test no. Vessel type Depth range Depth of penetration Dosing
time (s)
Input acoustic power (W) Focal intensitya (W/cm2) Lesionb Vessel occlusionc
1 SFA Shallow 4.7 30 30e 225 472 Y N
2 DFA Deep 11.5 30 378 472 Y N
3 SFA Shallow 5.5 30 30 472 472 N N
4 DFA Shallowd 7.8 30 30 472 472 Y N
5g SFA Shallow 5.2 60 257 472 Y Partial
6 DFA Deep 10.5 60 211 266 Y N
7 SFA Deep 9.2 60 195 266 Y N
8 DFA Deep 11.0 60 218 259 Y N
9 DFA Deep 10.8 18 60 225 266 Y N
10h SFA Shallow 5.2 60 30f 257 472 Y Y
11 DFA Deep 10.7 60 223 266 Y N
12 SFA Shallow 5.6 60 249 486 Y N
Exps 1–4: animal #101; Exps 5–8: animal #104; Exps 9–12: animal #103
aIntensity values are spatial average and temporal average; all foci superposed with attenuation derated according to each respective beam path
bStatus as regards the question: lesion around target region? (targeting assessment)
cOcclusion determined by reduction or stop of flow as evidenced in post-therapy angiography
dAlthough classified as shallow, location was at the border of the shallow-deep transition depth
eProlonged dosing procedure: second dose delivered 27 min after first dose; also one Tx (25 % of aperture) hit array thermal shutoff limits during 30-s dosing
fProlonged dosing procedure: second dose delivered 37 min after first dose
gPartial occlusion animal (#104); skin burns noted with TMM divoting of the PVA
hComplete occlusion animal (#103)
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Animal model acoustic complications
As described in reference [1], closed-loop localization of
the HIFU beam could be done via acoustic radiation
force impulse (ARFI) visualization of the beam focus
using 3D rendering of the tissue strain pattern created
by the focus in short test pulses. In this way, iterative
feedback-based correction of the targeted beam could be
done to align the beam with the vascular bleeder target.
Although this method was demonstrated in a few of the
in vivo treatments, the ARFI visualization was unable to
reliably detect the foci of the therapy beams, in large
part due to significant tissue motion induced by ventilator-
driven respiration. It was found that the levels of tissue
motion strain artifacts were on the same order as those in-
duced by the HIFU test pulses themselves used to enable
visualizing the focus. Thus, this problem was an artifact of
the testing procedure, likely not representative of actual
use of DBAC cuffs on limbs. In the future, however,
motion compensation image processing will likely be
necessary to properly segment and detect the ARFI-
imaged targeting beam in the context of motion. In
addition, D&L temporal image compounding, used to
capture all arterial flow image data, was also affected
by motion from ventilator-driven respiration, such as
producing flash artifacts due to the extended acquisi-
tion times. Fortunately, a DBAC cuff device used on
human extremities, being intimately pressed and clamped
against the anatomy, should be more stable from a relative
motion perspective when compared with the reported in
vivo test.
Although the maximum thermal skin dose (MTSD) re-
quirement was met, in 5 of 12 treatments, which were
all shallow bleeders (≈50-mm deep), localized burns did
occur on the actual animal skin. In these animals, the
bleeder-branch target points were sometimes close to
the skin (≈13–25 mm), thus requiring a TMM standoff
(e.g., 3-cm thick). Unlike the case of an actual human
DBAC treatment, this put the HIFU foci in proximity to
the skin and the TMM-skin interface. In the skin burn
cases, up to four small circular (d ≈ 5 mm) skin lesions
occurred, usually in regular patterns matching thermal
simulations, reflecting each active Tx array’s beam path
through the skin. In this circumstance, some of the
beams appeared to heat the TMM to a softening point
and, when combined with the radiation force of the
beam foci, created voids (5-mm diameter divots) in the
TMM surface (visually confirmed post-experiment). The
melting (divoting) of PVA standoffs seemed to occur
more consistently when using 30-s doses (requiring higher
intensities) in comparison to 60-s doses. Although only
occurring in a small proportion of the treatments, the
TMM divots are speculated to have contributed to the
skin burns via acoustic reflections generated next to the
skin. It is also possible that the voids reduced acoustic
coupling and that the skin lesioning increased acoustic
absorption at the skin surface. These behaviors, artifacts
specific to this setup to achieve deep treatments, may have
reduced energy delivery to the targets.
DBAC efficacy
Achieving hemostasis, defined as coagulative occlusion
of the target arteries, was the criterion for treatment
success. Modest acute reductions in SFA blood flow
were confirmed in one test subject. However, with the
exception of the right SFA in animal #103 (complete
occlusion, Fig. 13a) and left SFA in animal #104 (partial
occlusion, Fig. 13b), there were no demonstrable differ-
ences between the baseline and post-therapy angiograms.
Fig. 12 Immediate postmortem evaluation of the SFA in animal #103. (Tissue exam from that of test #10 in Table 3.) Note the dramatic difference
in the visual appearance of the common femoral artery and the SFA target vessel (vertical arrows)
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Although angiography is a very sensitive indicator of vessel
patency, it is less able to discern changes in the target ves-
sels consistently seen on histopathology, which included
evidence of blood clotting and collagen denaturation in all
targeted SFAs. Interestingly, in the complete occlusion
case, the SFA bleed flow rate reduced after the first dose
but then appeared to slightly increase after the second
dose, supporting the notion that occlusion occurred sig-
nificantly after the dosing. None of the angiograms showed
occlusion of the deep femoral artery, although DFA con-
striction was clearly evident in animal #104 based on angi-
ography and necropsy observations.
Acoustic streaming
The tourniquet function is needed to arrest net flow in
the blood vessels, both to limit bleeding of the patient
but also to minimize dissipation of the thermal energy
and limit washout of coagulative components. Such dis-
sipation is also possible from blood motion induced by
the acoustic radiation force of the therapeutic beam it-
self (acoustic streaming).
Unlike a direct arterial puncture wound, which would
produce blood leakage into the parenchymal tissue sur-
rounding the vessel (constraining its movement), blood
treated acoustically in a vessel is subject to acoustic
streaming. This streaming “mixes” the blood, in effect,
in an elongated tubular vessel cavity, with individual
blood sub-volumes undergoing significant motion dur-
ing the dose due to streaming. This behavior moves tar-
get blood in and out of the acoustic focal field and
towards and away from portions of the vessel wall being
heated. Further, enhanced convective cooling loss oc-
curs as blood travels back and forth from warmer to
cooler areas of the blood-filled vessel cavity. In the in-
tact SFA, conditions do not constrain the blood to the
treated region; thus, dwell time in the heated zone is
decreased.
FEM thermal and fluid dynamic simulations of
streaming effects on tissue heating were performed by
applying the radiation force as a momentum source to
the blood pool in the vessel (similar to the methods of
reference [5]), including applying a blood viscosity vs.
temperature mechanism. Figure 16 shows a representa-
tive simulated temperature field in two orthogonal
planes after a 30-s dose, with the focus being approxi-
mately 3 mm from the vessel wall. A 2-mm blood vessel
is represented in Fig. 16a, and a 5-mm blood vessel in
Fig. 16b (a typical porcine SFA in these studies was ap-
proximately 3 mm). With a baseline temperature of
37 °C, a maximum Teod = 86 °C was achieved in tissue,
while the blood in the 2-mm vessel had a Teod = 66 °C
(Fig. 16a), and merely a Teod = 47 °C for the blood in
the bigger vessel (Fig. 16b). Blood itself is a poor ab-
sorber of sound (α ≈ 0.2 dB/cm/MHz) and thus must
derive most of its thermal exchange from contact (con-
vective transfer) with tissue, so the vessel size has a
significant impact on the flow pattern and thus the
convective heat loss.
These streaming effects were experimentally confirmed
(vs. simulations) in in vitro test phantoms and relate to
the current in vivo results. Analysis of the partial occlu-
sion treatment in animal #104, for example, showed that
for the 60-s dose at 472 W/cm2 focal intensity (spatial
average, temporal average), a peak acoustic streaming
velocity of 6.1 cm/s is produced in the 3-mm SFA. This
produced significant thermal dissipation in the blood, not-
ing that the vessel-surrounding tissue had a Teod = 91 °C,
Fig. 13 a Complete bleeder track occlusion. Angiogram in animal
#103 (test #10 in Table 3) showing (post-treatment) the occluded
SFA tract. b Partial bleeder track occlusion. Angiogram showing
significantly narrowed femoral artery at the branch point of the SFA
in animal #104 (test #5 in Table 3). A subsequent angiogram
documented substantially reduced flow through the SFA. Histology
showed notable changes to the CFA in this treatment, unlike the
“parent vessels” in all other treatments
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while the blood was only Teod = 59.5 °C, on the low end of
even fixed-temperature coagulation thresholds in the lit-
erature with these dwell times (60–70 °C; see Figure one in
reference [1]). Also, even more thermal dissipation in the
blood would likely occur in vivo (vs. the in vitro simulation
results), since in vivo, the net radiation force was oriented
at an acute angle to vessel axis, not orthogonal to it.
Dose exposure time
Regarding coagulation efficacy, the required dose expos-
ure limit of ≤30 s was inadequate for efficacy in this
model, noting that the DBAC acoustic regime was predi-
cated on “thermal coagulation” delivered by an autono-
mous device (for safety reasons it depends on controlled
acoustic and heating behavior and avoiding unstable
non-linear regimes). Also regarding control, due to high
Tx driving voltages with 30-s doses, tile thermal man-
agement was more tractable for 60-s doses than 30-s
doses (normalized to equivalent total dose energy), e.g.,
avoiding pre-set array thermal shutoff limits.
Therapeutic acoustic regime
Although a thermal blood coagulation strategy was
used in this study, both heat and mechanical stimuli
can accelerate the coagulation cascade. Studies on the
effect of ultrasound on platelets have demonstrated in
vitro that therapeutic intensities can decrease the time
to form a clot [6], and increase platelet aggregation, a
key step in the coagulation cascade (likely through
shear stress on surface membranes) [7]. Reinforcement
of the hemostatic process may come from ultrasound
enhancement of platelet activation [8], also attributable
to acoustic shear forces and stimulation of platelets. It
is noteworthy, however, that for significant platelet ag-
gregation and activation increases to be produced by
mechanical effects of ultrasound at acoustic frequencies
relevant to DBAC, high focal intensities are required
(e.g., I > 1000 W/cm2 at fc = 1.1 MHz) [9]. Since such
intensities at these frequencies are capable of producing
cavitation, associated with the production of gas bub-
bles in the tissue, they come with potential complica-
tions regarding treatment control and safety.
Fig. 14 Histopathologic evaluation of the right SFA of animal #103. (Tissue exam from that of Test #10 in Table 3.) Demonstrates complete
luminal occlusion (left panel). Additional findings included transmural necrosis of smooth muscle cells in the vessel media and marked basophilic
degeneration of the collagenous substrate in the adventitial region
Fig. 15 Representative histologic section from parent vessel immediately proximal or distal to target vessels. The lack of histologic changes in the
vessels in intimate proximity to the target area is believed to support the accuracy of the targeting
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It is speculated that non-thermal effects (the coagula-
tion cascade) would likely have been suppressed in the
SFA model due to the nature of the intact vessel. Since
there was no vessel wall break, minimal direct contact of
adventitial collagen with platelets occurred (which would
have enhanced a normal coagulation cascade, triggering
adhesion, leading to platelet activation, release of clot-
ting factors, and progressing to platelet aggregation) [1].
Also relevant is the fact that an anti-coagulant (heparin)
was required in this model.
Hemostasis using higher acoustic intensities has been
demonstrated in bleeding vessels and organs [10–12]. In
these earlier studies, the HIFU applicators were hand-
held and moved during treatment, so it is difficult to
interpret their time and spatially averaged intensities
achieving hemostasis. These treatments involved surface,
or near-surface, bleeding targets (less than 5-mm deep)
with applicators that had water or metal coupling struc-
tures delivering highly localized power to the tissues
(avoiding the attenuation losses that would apply to
DBAC). In treating surgically exposed punctured blood
vessels with intensities of 2500 and 3100 W/cm2 with a
3.5-MHz device, and using 500 and 2000 W/cm2 with a
2.0-MHz device (up to 3 min) [10], it was speculated
that hemostasis was achieved through largely thermal ef-
fects, but the investigators indicated that it was un-
known if cavitation was present. In performing
hemostasis in lacerated liver [11] and spleen [12], high
intensities (3000 W/cm2; pressures ≈ 4 MPa) were also
used to achieve hemostasis but required relatively long
average exposures (78 ± 44 and 96 ± 33 s, respectively).
Interestingly, these organ hemostasis investigations did
associate bleeding cessation with end-of-dose tempera-
tures >70 °C (thermal mechanism) but reported the hist-
ology showed “homogenization” of the tissue, suggesting a
strong mechanical effect. These studies used 9.6-MHz
ultrasound, very absorptive for heating, but a frequency
much too high for DBAC penetration needs.
Similar to findings in the current study, heating has
long been known to occlude small blood vessels in sur-
gery due to vessel wall constriction (from collagen
shrinkage). Here the shrinkage force must overcome
blood pressure, and the temperature required for colla-
gen shrinkage increases with increasing load or tension
(i.e., with blood pressure). The tensile strength of the
collagen becomes stronger with higher temperature ex-
posure [13] and, for a sustained temperature range 65 °C ≤
T ≤ 90 °C, showed maximum shrinkage (20–40 %) for
 Temperature field around a 2mm vessel
vessel vessel
Top view Cross-sectional view
Temperature field around a 5mm vessel
Top view Cross-sectional view
vesselvessel
streaming 






Fig. 16 Temperature and acoustic streaming flow in the tissue medium with intact blood vessels of different size. Vessel is to the right of the
central hot spot in each view. The fluid flow induced by acoustic streaming for the 5-mm vessel case (b) is shown in (c). The peak streaming
velocity was 8.1 cm/s for the 2-mm vessel case (a) and 23.9 cm/s for the 5-mm vessel case (b)
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exposures of 10 to 30 s [14], suitable for the DBAC applica-
tion. Arterial hemostasis mediated by small artery
collagen shrinkage has been shown to require tem-
peratures in excess of 70 to 75 °C [13] for several
seconds of heat exposure. Thus, small artery vessel
shrinkage is a desirable supplemental mechanism to
reinforce wound hemostasis.
Summary and conclusion
A DBAC device was developed and tested in vivo, on
porcine SFA (and DFA) bleeders. The applicator system
was evaluated in a refereed in vivo final exam compris-
ing 12 bleeder treatments (six SFA and six DFA targets)
in three swine. All required elements of the testing
were administered (except the maximum bleeder depth
was 11.5 cm, not 12.5 cm). In vivo acoustic thermom-
etry and ARFI-based closed-loop targeting were demon-
strated, but unlike the case reported for the reference [1]
system, they were not used to guide and monitor the in
vivo treatments. Targeting, based on initial D&L coordi-
nates alone without correction, showed 92 % of lesions
centered on their vessel segment target areas. The over-
all image acquisition and D&L processing time for all
tests was <5 min, well below the 10-min limit. Two
D&L tests were unsuccessful with respect to bleeder
characterization, both being “low flow” bleeders and er-
roneously indicated as non-bleeder vessel bifurcations.
The primary automation objective was achieved, with
only a few “manual” steps being inserted during the test-
ing. Specifically, the “two-button” treatment was satisfied
but required manual switching (between imaging sys-
tems) of the Ix probe connectors, and manual targeting
markers were placed for the DFA bleeders (since they
were not catheterized).
For the primary objective of hemostasis, the required
dose exposure limit of 30 s was found inadequate for
this treatment regime, so 60-s dosing and dual-dosing
was explored. Acute reductions in blood flow (20–30 %)
were achieved in one subject, but only two SFA vessel
occlusions (one partial, one complete) were confirmed
angiographically. The successful complete coagulative
occlusion was achieved with a double dose (60 + 30 s =
90 s total) using a spatial- and time-averaged focal inten-
sity approaching I ≈ 500 W/cm2. Although angiography
indicated that hemostasis may have been partly due to
vessel wall constriction (collagen shrinkage), gross and
microscopic histopathology showed a thrombogenic
effect on targeted arteries, contributing to accumulating
vascular embolization. Encouragingly, the collateral dam-
age assessment indicated the treatments to be localized
and accurately targeted, with most treatments showing
minimal histologic effects on surrounding structures,
including the parent artery (CFA).
The SFA/DFA porcine model was the most suitable ani-
mal model to meet specified in vivo parameter ranges. In
addition, the model was stable throughout the long
(multi-hour) test protocols. The animal model was, how-
ever, imperfect in simulating DBAC cuff treatment on hu-
man limbs, especially regarding the means needed to
achieve bleeder depth and flow rate control, and the
device-tissue relative motion induced by ventilator-
supported breathing. In particular, the TMM standoffs
used to address the need for greater target depths came
at a cost of impacting acoustic performance and adding
logistical challenges. The use of an intact vessel as the
surrogate bleeder was a necessary compromise, in that
a direct-puncture wound would have rendered too diffi-
cult the quantification and control of blood flow rates.
Had a direct-puncture arterial wound been possible (es-
pecially without heparinization), a more realistic and
biologically accurate model may have resulted (e.g., co-
agulation cascade activity), one also amenable to more
effective blood heating (e.g., due to disruption of acous-
tic streaming). While significant accomplishments were
made with the SFA/DFA approach, the model con-
straints suggest that an improved animal model be
further pursued in future in vivo bleeder testing.
If not meeting all in vivo objectives, the performance
of the animal DBAC applicator results were positive. In
particular, as supported by the automated sequence
execution, the D&L results showed accurately targeted
multi-array power delivery, and based upon the evi-
dence of collagen denaturation and thrombogenesis in
the targeted vessels, the performance of this research
prototype system was encouraging.
Endnotes
1The DBAC device design and objectives were guided
by the requirements and milestones agreed to with re-
gard to the Phase II DBAC Cuff Contract, DARPA
HR0011-08-3-0004.
2The Texas Institute for Preclinical Studies (TIPS),
Texas A&M University, provided the test facility and
administered the in vivo test bed tests, with assistance
from University of Washington test monitors. The
DBAC animal model was developed jointly at TIPS and
University of Washington Center for Industrial and
Medical Ultrasound (CIMU).
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ACUSON SC2000: Siemens commercial ultrasound imaging system;
ARFI: acoustic radiation force impulse imaging; B-mode: ultrasound gray
scale imaging; CAD: computer-assisted design; CIMU: Center for Industrial
and Medical Ultrasound (at University of Washington); CFA: common femoral
artery; DARPA: Defense Advanced Research Projects Agency; D&L: detection
and localization; function/subsystem for finding bleeder sites; C7F2: a 2D
imaging probe (used to supplement and backup the 4Z1c); DBAC: Deep
Bleeder Acoustic Coagulation; DFA: deep femoral artery—the vessel branch
used for deeper bleeder targets; a continuation segment of the femoral
artery beyond SFA bifurcation; fc: acoustic center frequency (in MHz);
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FEM: finite element method (computational modeling method); HIFU: high-
intensity focused ultrasound; I: acoustic intensity (in W/cm2); Ix: imaging
probe/transducer or imaging probe functions; MTSD: maximum thermal skin
dose: Teod ≤ 52 °C, or ΔTskineod≤ 20 °C; P-mode: power Doppler flow
imaging mode; PVA: polyvinyl alcohol (base material for TMM used in
standoffs); RI: Resistive Index; RNN: recurrent neural network; method used in
acoustic thermometry for this project; SD: Spectral Doppler (ultrasound flow
velocity measurement method); SFA: superficial femoral artery (vessel branch
defined as a bleeder); T: temperature (in °C); Teod: end-of-dose temperature;
TIPS: Texas A&M Institute for Preclinical Studies; TMM: tissue-mimicking
material—used for surrogate tissue standoffs; Tx: therapeutic array or
therapeutic array functions; α: coefficient of acoustic attenuation/absorption
(in dB/cm/MHz); ΔTeod: end-of-dose temperature rise relative to baseline
temperature starting point; 4Z1c: ultrasound 3D volume imaging probe
(connected to ACUSON SC2000 imager).
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